Combined, Reduced-Antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix®)A Review of its Use as a Single-Dose Booster Immunization in Individuals Aged 10–64 Years in the US

被引：0

作者：

Greg L. Plosker

机构：

[1] Wolters Kluwer Health ¦ Adis,

[2] Wolters Kluwer Health,undefined

来源：

BioDrugs | 2009年 / 23卷

关键词：

Pertussis; Diphtheria; Diphtheria Toxoid; Seroprotection Rate; Pertussis Antigen;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：253 / 267

页数：14

共 37 条

[21] Combined reduced-antigen content tetanus, diphtheria, and acellular pertussis (Tdap) vaccine- related erythema nodosum: Case report and review of vaccine-associated erythema nodosum
Cohen P.R.
[J]. Dermatology and Therapy, 2013, 3 (2) : 191 - 197
[22] Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women
Sompagdee, Nalat
Anuwutnavin, Sanitra
Phongsamart, Wanatpreeya
Senawong, Sansnee
Umrod, Pinklow
Robkhonburi, Amporn
[J]. VACCINE, 2020, 38 (12) : 2725 - 2733
[23] Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults
Grimprel, E
von Sonnenburg, F
Sänger, R
Abitbol, V
Wolter, JM
Schuerman, LM
[J]. VACCINE, 2005, 23 (28) : 3657 - 3667
[24] Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine
Tomovici, A.
Barreto, L.
Zickler, P.
Meekison, W.
Noya, F.
Voloshen, T.
Lavigne, P.
[J]. VACCINE, 2012, 30 (16) : 2647 - 2653
[25] Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults
Kovac, Martina
Rathi, Niraj
Kuriyakose, Sherine
Hardt, Karin
Schwarz, Tino F.
[J]. VACCINE, 2015, 33 (22) : 2594 - 2601
[26] Tdap5 Vaccine (Covaxis®) A Review of its Use as a Single-Booster Immunization for the Prevention of Tetanus, Diphtheria, and Pertussis in Children (Aged ≥4 Years), Adolescents, and Adults
Scott, Lesley J.
[J]. BIODRUGS, 2010, 24 (06) : 387 - 406
[27] Tdap5 Vaccine (Covaxis®)A Review of its Use as a Single-Booster Immunization for the Prevention of Tetanus, Diphtheria, and Pertussis in Children (Aged ≥4 Years), Adolescents, and Adults
Lesley J. Scott
[J]. BioDrugs, 2010, 24 : 387 - 406
[28] Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA
Pool, Vitali
Tomovici, Antigona
Johnson, David R.
Greenberg, David P.
Decker, Michael D.
[J]. VACCINE, 2018, 36 (17) : 2282 - 2287
[29] Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults
Brandon, Donald
Kimmel, Murray
Kuriyakose, Sherine O.
Kostanyan, Lusine
Mesaros, Narcisa
[J]. VACCINE, 2018, 36 (42) : 6325 - 6333
[30] Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
Kovac, Martina
Kostanyan, Lusine
Mesaros, Narcisa
Kuriyakose, Sherine
Varman, Meera
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1977 - 1986

← 1 2 3 4 →